Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir

The efficacy of entecavir (ETV) monotherapy in treatment-experienced patients with chronic hepatitis B (CHB) is debatable. A total of 22 hepatitis B e antigen (HBeAg)-positive CHB patients who had shown viral breakthrough or suboptimal response with lamivudine (3TC) and adefovir disoproxil (ADV) the...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral therapy 2009-01, Vol.14 (7), p.985-993
Main Authors: WON HYEOK CHOE, SUN PYO HONG, KIM, Soo-Ok, CHANG HONG LEE, SO YOUNG KWON, BYUNG KOOK KIM, SOON YOUNG KO, YOUNG KUL JUNG, JI HOON KIM, JONG EUN YEON, KWAN SOO BYUN, KIM, Kyun-Hwan, SEUNG IL JI
Format: Article
Language:English
Subjects:
Adenine - analogs & derivatives
Adenine - therapeutic use
Adult
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Antiviral Agents - administration & dosage
Biological and medical sciences
DNA, Viral - analysis
DNA, Viral - genetics
Drug Resistance, Multiple, Viral - genetics
Evolution, Molecular
Female
Guanine - administration & dosage
Guanine - analogs & derivatives
Hepatitis B virus
Hepatitis B virus - drug effects
Hepatitis B virus - genetics
Hepatitis B, Chronic - drug therapy
Hepatitis B, Chronic - virology
Human viral diseases
Humans
Infectious diseases
Lamivudine - therapeutic use
Male
Medical sciences
Middle Aged
Mutation
Organophosphonates - therapeutic use
Pharmacology. Drug treatments
Treatment Outcome
Viral diseases
Viral hepatitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The efficacy of entecavir (ETV) monotherapy in treatment-experienced patients with chronic hepatitis B (CHB) is debatable. A total of 22 hepatitis B e antigen (HBeAg)-positive CHB patients who had shown viral breakthrough or suboptimal response with lamivudine (3TC) and adefovir disoproxil (ADV) therapy were treated with 1.0 mg of ETV. Clinical and virological parameters were monitored every 3 months. Restriction fragment mass polymorphism assays were used to detect antiviral resistance. During 3TC and ADV therapy, 11 patients had rtM204V/I mutations, 2 had rtA181V/T or rtN236T, 7 had both and 2 had no 3TC- or ADV-related mutations. After switching to ETV monotherapy, the median change in serum hepatitis B virus (HBV) DNA level was -2.1 log(10) copies/ml. Virological response (HBV DNA
ISSN:1359-6535
2040-2058
DOI:10.3851/IMP1417